AdipoGen Life Sciences

(R)-BI-2536

Product Code:
 
SYN-1019
Product Group:
 
Inhibitors and Activators
Regulatory Status:
 
RUO
Shipping:
 
-20°C
1 / 1
Chemical Structure
❮❯

Chemical Structure

No additional charges, what you see is what you pay! *

CodeSizePrice
SYN-1019-M100100 mgEnquire
Quantity:
SYN-1019-M0011 mg£104.00
Quantity:
SYN-1019-M0055 mg£145.00
Quantity:
SYN-1019-M01010 mg£238.00
Quantity:
SYN-1019-M05050 mg£771.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Related Products
  • Show All

Further Information

Alternate Names/Synonyms:
(R)-BI2536
Appearance:
Solid.
CAS:
755038-02-9
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C28H39N7O3/c1-5-22-27(37)34(3)23-17-29-28(32-25(23)35(22)20-8-6-7-9-20)31-21-11-10-18(16-24(21)38-4)26(36)30-19-12-14-33(2)15-13-19/h10-11,16-17,19-20,22H,5-9,12-15H2,1-4H3,(H,30,36)(H,29,31,32)/t22-/m1/s1
InChiKey:
XQVVPGYIWAGRNI-JOCHJYFZSA-N
Long Description:
Chemical. CAS: 755038-02-9. Formula: C28H39N7O3. MW: 521.7. Polo-like kinase 1 (Plk1) is a regulator of the cell cycle that has been implicated in the pathology of many cancers. BI-2536 is a potent and selective small-molecule inhibitor of mammalian Plk1. It has inhibitory activity at subnanomolar concentrations and inhibits tumor growth in multiple tumor lines with IC(50) values below 1µM. BI-2536 also shows an >1,000-fold selectivity for PIK1 versus a large panel of other kinases. BI-2536 also demonstrated low Kd values against sister kinases PLK2 and PLK3. Preclinical studies in human cancer cell lines have shown that BI 2536 disrupts spindle assembly, resulting in mitotic arrest and inducing apoptosis. BI-2536 is currently in clinical trials against several types of solid tumor cancers.
Molecular Formula:
C28H39N7O3
Molecular Weight:
521.7
Package Type:
Plastic Vial
Product Description:
Polo-like kinase 1 (Plk1) is a regulator of the cell cycle that has been implicated in the pathology of many cancers. BI-2536 is a potent and selective small-molecule inhibitor of mammalian Plk1. It has inhibitory activity at subnanomolar concentrations and inhibits tumor growth in multiple tumor lines with IC(50) values below 1µM. BI-2536 also shows an >1,000-fold selectivity for PIK1 versus a large panel of other kinases. BI-2536 also demonstrated low Kd values against sister kinases PLK2 and PLK3. Preclinical studies in human cancer cell lines have shown that BI 2536 disrupts spindle assembly, resulting in mitotic arrest and inducing apoptosis. BI-2536 is currently in clinical trials against several types of solid tumor cancers.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO, Ethanol
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo: M. Steegmaier, et al.; Curr. Biol. 17, 316 (2007) | Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors: H.Y. Wang, et al.; Bioorg. Med. Chem. Lett. 18, 4972 (2008) | Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors: Q. Zhang, et al.; Bioorg. Med. Chem. Lett. 22, 7615 (2012) | HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents: M. McMahon, et al.; PLoS One 9, e114055 (2014)